Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672847 | 0.92 | MCHR1 (0.45) | MAOBTSHRL3MBTL1CNR2CA1 | |
| SCHEMBL5743428 | 0.91 | MAOB (0.51) | MAOBBCHEACHEDRD1DRD3 | |
| SCHEMBL24012573 | 0.82 | HDAC3 (0.45) | MAOBTSHRBCHEACHEKDM4E | |
| SCHEMBL14192202 | 0.82 | MCHR1 (0.55) | MAOBCNR2CA12CA1CA2 | |
| SCHEMBL5746057 | 0.80 | SMN1; SMN2 (0.55) | MAOBTSHRBCHEACHE | |
| SCHEMBL5673877 | 0.80 | MAOB (0.51) | MAOBTSHRMAPK1BCHEACHE | |
| SCHEMBL615299 | 0.80 | TSHR (0.56) | MAOBTSHRMAPK1BCHEACHE | |
| SCHEMBL4902679 | 0.79 | HDAC3 (0.49) | MAOBTSHRBCHEACHEKDM4E | |
| SCHEMBL4499222 | 0.79 | SMN1; SMN2 (0.51) | TSHRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14890694 | 0.78 | TSHR (0.50) | TSHRCYP1A2CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288198-B1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1549761-A4 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | VI TECHNOLOGIES INC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6992205-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2006-01-31 | — | — | US | disclosed |
| EP-1549761-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | V.I. Technologies, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6864372-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6794519-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2004-09-21 | — | — | US | disclosed |
| WO-2003093512-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | V.I. TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030176711-A1 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162966-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | TST, STS, SELENOI | MAOB 3129/4885TSHR 467/4885MAPK1 816/4885 |
| US-20030176711-A1 | Process for the production of sulfonic esters | TST, STS, SELENOI | MAOB 3129/4885TSHR 467/4885MAPK1 816/4885 |
| US-20030176713-A1 | Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base | BRAF, ADH1C, TST | MAOB 3182/4885TSHR 395/4885MAPK1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.